"Efficacy and safety of Liangxue Jiedu decoction for the treatment of progressive psoriasis vulgaris: a multicenter, randomized, controlled study".

"Efficacy and safety of Liangxue Jiedu decoction for the treatment of progressive psoriasis vulgaris: a multicenter, randomized, controlled study". J Tradit Chin Med. 2020 Apr;40(2):296-304 Authors: Sun L, Zhou D, Wang P, Li T, Xu X, Yang X, Tian J, Zhao J, He Y, Liu F, Tong C, Chu X, Dai L, Zhu W Abstract OBJECTIVE: To determine the clinical efficacy and safety of Liangxue Jiedu decoction (LJD) for the treatment of progressive psoriasis vulgaris and to provide the basis for the development of a standardized treatment protocol for psoriasis vulgaris. METHODS: In this multicenter, randomized, controlled study, patients with blood-heat type psoriasis were randomly assigned to receive either Chinese herbal medicine (LJD; treatment group) or Western Medicine (cetirizine hydrochloride, vitamin C, and vitamin B complex; control group). Psoriasis Area and Severity Index (PASI) scores were calculated in addition to the number of patients who achieved ≥ 50% or ≥ 75% improvement in PASI score from baseline. The change in symptoms of Chinese medicine (color of rash, burning sensation, itchiness, severity of irritation, and anger) was evaluated and safety was assessed as adverse events and laboratory analysis. t test, independent sample non-parametric test and χ2 test were used to analyze the results. RESULTS: A total of 238 participants were included in the study [treatment group, n = 122 (PP analysis 117); control group, n = 116 (PP a...
Source: Journal of Traditional Chinese Medicine - Category: Complementary Medicine Authors: Tags: J Tradit Chin Med Source Type: research

Related Links:

Conclusion: In this work, we have successfully illuminated that Qubi Formula could relieve a wide variety of pathological factors (such as inflammatory infiltration and abnormal angiogenesis) of psoriasis in a "multicompound, multitarget, and multipathway" manner by using network pharmacology. Moreover, our present outcomes might shed light on the further clinical application of QBF on psoriasis treatment. PMID: 32655662 [PubMed]
Source: Evidence-based Complementary and Alternative Medicine - Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research
Research has shown ixekizumab improves pain and the sexual health of patients with genital psoriasis...
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: DMARDs & Immunosuppressives Drug Updates genital psoriasis ixekizumab sexual health Source Type: research
Topical roflumilast brought marked improvement in signs and symptoms of chronic plaque psoriasis in a phase 2b trial."Roflumilast cream could really be a game changer," said a trial investigator.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Dermatology News Source Type: news
Conditions:   Psoriasis;   Metabolic Syndrome Interventions:   Drug: Secukinumab;   Drug: Methotrexate Sponsor:   Universita di Verona Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
HORSHAM, PA, July 14, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab) for adult patients with active psoriatic arthritis (PsA), a chronic progressive disease characterized by painful joints and skin inflammation.[1],[2] TREMFYA is the first treatment approved for active PsA that selectively inhibits interleukin (IL)-23, a naturally occurring cytokine that is involved in normal inflammatory and immune responses associated with the symptoms of PsA. The safety and efficacy of TREMFYA in PsA have be...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
Conclusion: Only one third reached dietary intake of folate, but deficiencies of folate and B12 were low. Psoriasis severity was negatively correlated with circulating folate and B12. Stopping smoking and a folate rich diet may be important targets for managing psoriasis.
Source: Current Nutrition and Food Science - Category: Nutrition Source Type: research
Pituitary adenylate cyclase activating polypeptide (PACAP) is a neuropeptide widely distributed in the nervous system, where it exerts strong neuroprotective effects. PACAP is also expressed in peripheral organs but its peripheral protective effects have not been summarized so far. Therefore, the aim of the present paper is to review the existing literature regarding the cytoprotective effects of PACAP in non-neuronal cell types, peripheral tissues, and organs. Among others, PACAP has widespread expression in the digestive system, where it shows protective effects in various intestinal pathologies, such as duodenal ulcer, ...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Source Type: research
In this study, we investigated whether and how sirtuin 2 (Sirt2) deacetylase regulated the protein kinase function of PKM2 in Th17 cell-mediated inflammatory responses in psoriasis. Sirt2 KO mice and WT littermates had psoriatic dermatitis induced by topical treatment of imiquimod or intradermal injection of recombinant IL-23.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Original Article Source Type: research
​​The company is marketing the drug as a replacement to Roche’s tocilizumab (originally approved for rheumatoid arthritis) that is currently in off-label use among Covid-19 patients who suffer from cytokine release syndrome (CRS).
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: China Health | Complementary Medicine | Herbs | Laboratory Medicine | Psoriasis | Skin | Statistics | Study | Vitamin B | Vitamin C | Vitamins | Zyrtec